---

Related Articles:

Role of a small molecular weight phosphoprotein in the mechanism of action of CI-994 (N-acetyldinaline).

1995-09-04

[Int. J. Cancer 62(5) , 636-42, (1995)]

Phase I study of oral CI-994 in combination with carboplatin and paclitaxel in the treatment of patients with advanced solid tumors.

2004-01-01

[Cancer Invest. 22(6) , 886-96, (2004)]

Cytotoxic chemotherapy regimens that increase dose per cycle (dose intensity) by extending daily dosing from 5 consecutive days to 28 consecutive days and beyond.

2000-06-01

[Clin. Cancer Res. 6(6) , 2474-81, (2000)]

Immunotoxicity of the anticancer drug CI-994 in rats: effects on lymphoid tissue.

1999-01-01

[Arch. Toxicol. 73(3) , 168-74, (1999)]

In vivo development of an acetyldinaline resistant subline of the BN rat acute myelocytic leukemia (BNML).

1993-08-01

[Leukemia 7(8) , 1275-80, (1993)]